Dipal Doshi, President and CEO at Entrada Therapeutics, Inc. (TRDA), sold 24,622 shares at $20.01 ($509K) on 2022-10-25, disclosed to the SEC on 2022-10-27.
Open-market sale of $509k TRDA by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.01 | 3,055 | $61K | 12.0% |
| 2 | $20.01 | 3,055 | $61K | 12.0% |
| 3 | $20.76 | 7,506 | $156K | 30.6% |
| 4 | $20.76 | 7,506 | $156K | 30.6% |
| 5 | $21.50 | 1,500 | $32K | 6.3% |
| 6 | $21.66 | 2,000 |
| $43K |
| 8.5% |
| Total | $20.69 avg | 24,622 | $509K | 100% |
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-02-20 | $15K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |